172@29@17@246!~!172@29@0@53!~!|news|business|demand-for-health-and-hygiene-products-would-remain-high-post-pandemic-itcs-sanjiv-puri-5808771.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Subscribe to Moneycontrol Pro and grab benefits worth ₹15,000/-
you are here: HomeNewsBusiness
Last Updated : Sep 07, 2020 06:56 PM IST | Source: Moneycontrol.com

Demand for health and hygiene products would remain high post pandemic: ITC's Sanjiv Puri

ITC's gross revenue and PBT (before exceptional items) for FY20 stood at around Rs 46,300 crore and Rs 19,300 crore, respectively

ITC products (Image: Moneycontrol)
ITC products (Image: Moneycontrol)
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

In a post-pandemic world, demand for certain categories, like health and hygiene and packaged food, would remain at an elevated level, and ITC would be prepared to cater to that demand, said Sanjiv Puri, chairman and managing director, ITC on September 7.

"In the new normal, we are seeing a surge in certain categories. When the pandemic gets over, certain categories will settle at an elevated level. When I say elevated level, it is in comparison to pandemic situation, but may not have the surge seen during the pandemic. So health and hygiene could be one such category, but the awareness and importance of simple things like hand washing and cleanliness would definitely go up," said Puri at a virtual press interaction.

He said the need to clean fruits and vegetables has been accentuated by the COVID-19 pandemic and with the availability of scientific solutions like ITC Nimwash, the demand for such things would increase going forward.

"Maybe sanitisers won't be at a level as today, but it will certainly be at an elevated level going forward. We also have to prepare now for the next normal... That's were the adaptability, creativity and resilience of the enterprises would be tested," Puri said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

He said as far as capacity is concerned, ITC has expanded its capacity way beyond its buffer capacity. "Our handwash, for example, is five to six times of what we were producing earlier. Capacity expansion has happened in house by commissioning some additional facilities... We have the infrastructure. What we need to do is we need to add machines over a period of time," Puri said.

Manufacture of ITC’s hygiene products like Savlon sanitisers was ramped up by 275 times to cater to the surge in demand. ITC ramped up production capacity and resumed distribution in record time, with focus on safety protocols. Over 180 factories manufacturing essential products in foods, personal care and hygiene as well as paperboards and packaging were progressively made operational.

More than 85 percent of ITC’s associated warehouses were made operational within 10 days of the lockdown.

ITC's gross revenue and PBT (before exceptional items) for FY20 stood at around Rs 46,300 crore and Rs 19,300 crore, respectively. Non-cigarette segment revenue rose to Rs 31,000 crore during the year, accounting for nearly 60 percent of ITC’s total segment revenue.

ITC’s FMCG brands clocked an annual consumer spend of over Rs 19,700 crore in aggregate during the year. Segment EBITDA (earnings before interest, taxes, depreciation and amortization) recorded a robust growth of 33 percent during the year.
First Published on Sep 7, 2020 06:56 pm
Sections